abstract |
The invention relates to a combination medicament for use in treatment of a cancer of an internal body cavity. The combination medicament comprises a TLR agonist formulated for local administration in a thermo-reversible hydrogel composition, and an immune checkpoint inhibitor selected from the group consisting of an anti-PD1, anti-PDL1, and anti-CTLA4, formulated for local administration in a thermo-reversible hydrogel composition. |